Epigenetic test for prostate cancer markers valuable

the ONA take:

New research suggests that an initial biopsy with an added epigenetic diagnostic test accurately rules out the existence of cancer up to 88 percent of the time, which could help exclude the need for repeat prostate biopsies for many individuals. repeat biopsies are often needed when screening for prostate cancer, so a different means of screening may provide a quicker conclusion to testing. The test in question captures the presence of chemical modifications to non-nuclear DNA sequences within cells associated with the presence of prostate cancer.

Epigenetic test for prostate cancer markers valuable
Epigenetic test for prostate cancer markers valuable
A multicenter team of researchers report that a commercial test designed to rule out the presence of genetic biomarkers of prostate cancer may be accurate enough to exclude the need for repeat prostate biopsies in many— if not most— men.
READ FULL ARTICLE From Biosciencetechnology
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs